Page last updated: 2024-09-04

canertinib and Exanthem

canertinib has been researched along with Exanthem in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bycott, P; Cunningham, C; Eiseman, I; Lenehan, PF; Nemunaitis, J; Olson, SC; Schlicht, M; Senzer, N; Shin, DM; Williams, A; Zentgraff, R; Zinner, RG1
Bonomi, PD; Butts, CA; Chiappori, AA; Cohen, RB; Crino, L; Dasse, K; Eiseman, IA; Jänne, PA; Lenehan, PF; Olson, SS; Sheeran, M; von Pawel, J; Yeap, BY1

Trials

2 trial(s) available for canertinib and Exanthem

ArticleYear
Phase 1 clinical and pharmacokinetics evaluation of oral CI-1033 in patients with refractory cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, May-15, Volume: 11, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Anorexia; Diarrhea; Drug Administration Schedule; Exanthema; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Morpholines; Neoplasms; Protein-Tyrosine Kinases

2005
Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Sep-01, Volume: 25, Issue:25

    Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Morpholines; Survival Rate

2007